A Novel, Noninvasive, Predictive Epilepsy Biomarker with Clinical Potential

A novel, noninvasive, predictive epilepsy biomarker with clinical potential.

A significant proportion of temporal lobe epilepsy (TLE), a common, intractable brain disorder, arises in children with febrile status epilepticus (FSE). Preventative therapy development is hampered by our inability to identify early the FSE individuals who will develop TLE. In a naturalistic rat model of FSE, we used high-magnetic-field MRI and long-term video EEG to seek clinically relevant n...

S100β: A Predictive Biomarker for Neural Trauma with Therapeutic Potential

for making both diagnoses and prognoses of neurological injury. Of the more than 20 isoforms in the S100 protein family, S100ß displays unique biomarker and diagnostic properties in ectodermic derived normal neurons and certain malignancies. The purpose of this focused review is to highlight and discuss findings that support the notion that S100ß can be used as a biomarker to indicate the prese...

cell free dna: a novel biomarker for clinical diagnosis

cell free dnas (cfdnas) are small fragments of genomic or mitochondrial dna releasing from cells into the blood stream. the presence of cfdna in the human circulatory system has been shown for the first time in 1948 however, the potential clinical applications of cfdna remained unknown until recent progress in detection and quantification of these molecules by sensitive methods. in this paper, ...

PD-L1 expression as a potential predictive biomarker.

Emergence of a Predictive Clinical Biomarker for Diabetic Neuropathy

Diabetes is often complicated by the development of neuropathy, with up to a third of the direct costs of diabetes attributed to neuropathyrelated morbidity (1). The incidence of diabetic neuropathy increases with duration of diabetes, affecting up to 50% of diabetic patients after 25 years of disease (2). To date, the development of neuroprotective and disease-modifying approaches for diabetic...